Bavarian Nordic

Major Shareholding Notification • Nov 26, 2013

Bavarian Nordic A/S - Major Shareholder Announcement

Bavarian Nordic A/S - Major Shareholder Announcement

KVISTGAARD, Denmark, November 26, 2013 - Bavarian Nordic A/S (OMX: BAVA) has received information from BB Biotech AG that the company has decreased its ownership in Bavarian Nordic to 4.95 % of the share capital in Bavarian Nordic.

Asger Aamund

Chairman of the Board

Contacts

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit www.bavarian-nordic.com.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

HUG#1745778

Attachments:

• 201323uk

  ---

  This content was distributed through

  

  Create value through communication

  Visit us here.